with at least 1 risk factor for cardiovascular disease) participating in a randomized controlled trial designed to compare the safety of tofacitinib to adalimumab The panel also considered PICO questions related to current use of checkpoint inhibitor therapy, but the variability in current practice patterns and differences in treatment for specific cancer types precluded the development of specific recommendations for patients who are candidates for, or are currently receiving checkpoint